Literature DB >> 10349786

[A relative bioavailability study of 2 oral formulations of omeprazole after their administration in repeated doses to healthy volunteers].

J P Richards1, M Gimeno, T A Moreland, J McEwen.   

Abstract

To determine the relative bioavailability of Ulceral (study formula) with respect to Losec (reference standard formula) and establish their bioequivalence daily doses of 20 mg of omeprazole were given during 5 consecutive days to 24 healthy volunteers. No significant differences were observed in the area under the curve (AUC0-t), a parameter directly related to the inhibition of acid secretion induced by omeprazole. The confidence interval of 90% for the difference between the two formulations for AUC0-t was within the interval of acceptance (0.80-1.25). The confidence interval for the difference between the two formulations for Cmax were also within the range of acceptance (0.70-1.43). In relation to the time for achieving (Cmax (tmax), the difference between the two formulations and the confidence interval of 95% for the tmax was 0.75 (-0.5-1.75) h indicating that no significant differences were observed between the two treatments. This study confirms the bioequivalence of Ulceral with the standard reference formulation as well as the tolerability of the two formulae.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10349786

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  2 in total

1.  Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions.

Authors:  Manuel Vaz-da-Silva; Ana I Loureiro; Teresa Nunes; Joana Maia; Susana Tavares; Amilcar Falcão; Pedro Silveira; Luis Almeida; Patricio Soares-da-Silva
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

2.  Relative Bioavailability of Two Enteric-Coated Formulations of Omeprazole following Repeated Doses in Healthy Volunteers.

Authors:  M Vaz-da-Silva; D Hainzl; L Almeida; A Dolgner; P Silveira; J Maia; P Soares-da-Silva
Journal:  Clin Drug Investig       Date:  2001-03       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.